Corteva, Inc.CTVA

Corteva, Inc. reported $4.91 billion in revenue for the quarter ending 31 March 2026, a figure that would look neat on a pitch deck but less so when paired with the $2.89 billion of negative operating cash flow in the same period. The company, which makes crop protection chemicals and seeds for soybeans, fruit, and vegetables, remains a giant in the field but a question mark in the cash cycle. Its latest 10-Q shows finished products valued at $3.04 billion sitting in inventory, a number that sounds impressive until you remember it’s tied up in warehouses rather than working capital. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1755672/000175567226000010/ctva-20260331.htm)

Corteva’s product pages read like a farmer’s dream board: herbicides, fungicides, insecticides, and seed solutions designed to keep soybeans standing tall and fruit markets crisp. The Enlist™ E3 soybean solutions page, for example, features a farmer grinning next to a combine, which is a neat trick if you ignore the fact that the combine’s fuel gauge is pointing to ‘empty’ on the cash flow statement. The company’s fruit and vegetable solutions page promises ‘collaboration, curiosity, and innovation’ to protect crops, but the balance sheet is more interested in the $5.2 billion of inventory and the $439 million reduction achieved in the quarter. (source: Official product/news rail, https://www.corteva.com/products-and-services/crop-protection/fruit-and-vegetable-solutions/how-collaboration-curiosity-and-innovation-protect-crops.html; https://www.corteva.com/products-and-services/soybean-solutions.html)

Under the bonnet, the numbers tell a story of a company still capable of profit-$720 million of net income and $1.07 diluted EPS for the quarter-but one that is haemorrhaging cash at the operating level. The 10-Q shows $1.96 billion in cash and equivalents, yet net cash used in operating activities was $2.89 billion, a gap that suggests the business is generating paper profits while starving itself of liquidity. Inventory shrank by $439 million, but at $5.2 billion, it remains a hefty line item on a balance sheet that is otherwise lean. Research and development spending of $341 million keeps the innovation pipeline flowing, but the question is whether the cash conversion cycle will ever catch up. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1755672/000175567226000010/ctva-20260331.htm)

The company’s restructuring program, first announced in an 8-K on 8 November 2023 and reaffirmed in an 8-K/A on 12 June 2026, is meant to streamline the business and improve margins. Yet the latest 11-K filing reveals the company’s employee stock purchase plan bought $9 million of Corteva shares in 2025 while selling $18 million, a pattern that looks less like employee enrichment and more like a discreet share-price support operation. The plan’s mandate may be noble, but the optics are awkward for a company that is still talking about restructuring. (source: SEC EDGAR 8-K/A, https://www.sec.gov/Archives/edgar/data/1755672/000175567226000020/ctva-20231108.htm; SEC EDGAR 11-K, https://www.sec.gov/Archives/edgar/data/1755672/1755672/20260611.htm)

The company’s remaining performance obligations tied to contract renewal options stand at $147 million as of 31 March 2026, a figure that sounds like future revenue but is also a reminder that promises don’t pay bills-cash does. The 10-Q also shows $138 million owed from customers to lenders under these agreements, a detail that adds another layer of complexity to the cash conversion story. Meanwhile, the company’s total assets stand at $42.72 billion, with stockholders’ equity at $24.36 billion, which is reassuring for solvency but less so for liquidity. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1755672/000175567226000010/ctva-20260331.htm)

The tension in Corteva’s story is visible in the numbers: revenue is up, but cash is down; inventory is shrinking, but still colossal; restructuring is promised, but the evidence of execution is thin. The company’s crop protection and seed businesses remain essential to global food chains, yet the balance sheet is sending signals that the business is not yet firing on all cylinders. The next filing that matters will be the Q2 2026 10-Q, due in early August, where the market will look for signs that the cash conversion cycle is tightening-or that the restructuring is finally delivering. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1755672)